What's Happening?
Silvia Cerolini, CEO of Eyes on the Future, is advocating for patient involvement in pharmaceutical innovation. Her efforts began after her daughter was diagnosed with an untreatable form of Inherited Retinal Dystrophy. Cerolini has raised over $6 million
and united families across 20 countries to drive progress in gene therapy and drug repurposing for rare eye diseases. Her mission emphasizes the role of patients as partners in discovery and drug development.
Why It's Important?
Cerolini's advocacy highlights the transformative potential of patient involvement in pharmaceutical research and development. By positioning patients as active partners, the initiative fosters collaboration and accelerates innovation in treatments for rare diseases. This approach challenges traditional research models and underscores the importance of patient voices in shaping healthcare solutions, potentially leading to more effective and personalized therapies.
